CYP3A5 and acute kidney injury: Expressers of CYP3A5 *1 spend significantly more time at subtherapeutic tacrolimus levels during the inpatient stay; however, once these patients reached therapeutic goals, the difference in AKI rates among patients with different genotypes disappeared.